doripenem
Phase 3Completed 1 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Bacterial Infections and Mycoses
Conditions
Bacterial Infections and Mycoses, Appendicitis, Cholecystitis, Pancreatitis, Peritonitis
Trial Timeline
Mar 1, 2004 → Mar 1, 2006
NCT ID
NCT00229060About doripenem
doripenem is a phase 3 stage product being developed by Johnson & Johnson for Bacterial Infections and Mycoses. The current trial status is completed. This product is registered under clinical trial identifier NCT00229060. Target conditions include Bacterial Infections and Mycoses, Appendicitis, Cholecystitis.
What happened to similar drugs?
5 of 20 similar drugs in Bacterial Infections and Mycoses were approved
Approved (5) Terminated (2) Active (14)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00986102 | Approved | Completed |
| NCT00211016 | Phase 3 | Completed |
| NCT00211003 | Phase 3 | Completed |
| NCT00210990 | Phase 3 | Completed |
| NCT00210938 | Phase 3 | Completed |
| NCT00229060 | Phase 3 | Completed |
Competing Products
20 competing products in Bacterial Infections and Mycoses